Typhoid fever market is set to reach US$ 858.77Million by 2033, at a CAGR of 9.7%. Asia Pacific leads the market with 42% market share.

The global Typhoid fever market size reached US$ 342.86Million with a rise of US$373.72Million in 2024 and is expected to reach US$ 858.77Million by 2033, growing at a CAGR of 9.7%during the forecast period 2025-2033.

Typhoid Fever market focuses on diagnostics, vaccines, and treatments targeting Salmonella Typhi infections, driven by rising global cases, healthcare advancements, and increasing demand for effective prevention and therapeutic solutions.

DataM Intelligence unveils its latest report on the "Typhoid Fever Market size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/typhoid-fever-market?prtk

United States: Key Industry Developments

✅ November 2025: PATH and EuBiologics announced promising Phase 3 results for the new typhoid conjugate vaccine EuTYPH-C Inj. Multi-dose, demonstrating strong safety, high seroconversion rates of 99.6%, and non-inferior immunogenicity compared to Typbar TCV in endemic populations.

✅ October 2025: A Phase 1 trial in the US showed a new dual-target Salmonella conjugate vaccine (TSCV) generated 100% immune responses against typhoid and non-typhoid Salmonella in healthy adults, with excellent safety and tolerability at tested doses.

✅ March 2025: CARB-X launched its 2025 funding round seeking therapeutics and diagnostics for Salmonella Typhi infections, including Gram-negative pathogens responsible for typhoid fever, to address global infectious disease threats.
​
Japan: Key Industry Developments

✅ November 2025: EuBiologics' EuTYPH-C Inj. Multi-dose typhoid conjugate vaccine received licensure from the Korean Ministry of Food and Drug Safety based on Phase 3 data, advancing potential access in Asia-Pacific regions including Japan amid typhoid vaccine market growth.

✅ July 2025: Japan's PMDA Joint Meeting reviewed safety data for typhoid-related vaccines, concluding no significant concerns from adverse reaction reports, supporting continued use without package insert revisions.

✅ January 2026: Reports highlighted ongoing expansion in Japan's typhoid fever vaccines market, valued with projections from prior years, driven by innovations in conjugate vaccines and routine immunization efforts.

📌 Typhoid Fever Market 2025-26 M&A Deals

→ In December 2025, Sanofi agreed to acquire Dynavax Technologies Corporation, a U.S.-based vaccine maker, in a deal valued at approximately US$2.2 billion expanding its overall vaccine portfolio (though not specific only to typhoid vaccines, it strengthens its broader infectious disease and adult vaccine presence which influences related vaccine markets). The acquisition is expected to close in Q1 2026 subject to regulatory approvals.

→ In October 2025, SK bioscience (a global vaccine developer including typhoid conjugate vaccine manufacturing) continued its strategic investments in vaccine technologies and capabilities building on prior acquisitions and partnerships intended to support advanced vaccine development for typhoid and other vaccines, though no specific monetary M&A figure strictly tied to typhoid assets was disclosed in 2025.

Zydus Lifesciences (developer of the typhoid conjugate vaccine ZyVac TCV) announced collaboration with the Bill & Melinda Gates Foundation to develop a combined Shigella & Typhoid vaccine an R&D partnership, not a traditional M&A, but significant strategic activity in the typhoid space.

Typhoid Fever Market Drivers:-
⏩ Rapid population increases coupled with urban sprawl in emerging economies concentrate populations in peri‐urban and slum areas where limited access to clean water and poor sanitation enable higher transmission rates. These social determinants directly translate to elevated demand for vaccines, diagnostics, and therapeutic interventions.

⏩ The rapid rise of multidrug‐resistant (MDR) and extensively drug‐resistant (XDR) Salmonella Typhi strains is one of the most transformative drivers in the market. As traditional antibiotics lose efficacy, reliance on vaccination and next‐generation therapeutic strategies has increased sharply.

⏩ Major global health bodies, including the WHO, Gavi, UNICEF, and national health ministries, have expanded support for typhoid vaccination programs. Recommendations to include typhoid conjugate vaccines (TCVs) in national immunization schedules have accelerated adoption rates, particularly among young children in high‐burden regions.

⏩ New vaccine technologies (e.g., improved conjugate vaccines with longer immunity) are replacing older formulations, expanding target age groups, and enabling broader immunization.

⏩ Diagnostics evolution, especially rapid and point‐of‐care (POC) tests, is improving detection rates and enabling timely intervention a key factor for health systems seeking cost‐efficient disease management pathways.

⏩ Rising investments in healthcare infrastructure fueled by economic growth, public health priorities, and private sector participation are enabling broader access to typhoid interventions. Governments are increasing healthcare budgets to strengthen delivery systems for vaccines, diagnostics, and treatments, especially in underserved regions.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=typhoid-fever-market?prtk

Typhoid Fever Major Players:-

Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, DAIICHI SANKYO COMPANY, LIMITED,GSK plc., AstraZeneca, Merck & Co., Inc., AbbVie Inc., Sanofi, and Johnson &Johnson, among others.

Key players highlights:-

GSK plc - A leading vaccine provider holding approx. 24% share in the typhoid vaccine segment, with strong global distribution and portfolio influence.

Pfizer Inc. - Major player in typhoid and broader vaccine markets with around 15% share, driven by R&D and global reach.

Sanofi - Key typhoid vaccine contributor with roughly 15% market share, supported by extensive immunization products worldwide.

Merck & Co., Inc. - Strong vaccine portfolio translating to about 11% share in related vaccine markets, positioning it high among competitors.

Johnson & Johnson - Diversified healthcare business holding around 7% share in travel and infectious disease vaccines including typhoid.

Typhoid Fever Regional Highlights

Asia Pacific
Asia Pacific dominates the global typhoid fever vaccine market, contributing around 42% of total revenue in 2023, driven by high disease prevalence and strong immunization initiatives in India, China, and Southeast Asia.
The region is also the largest for oral typhoid vaccines with an estimated 42.6% share in 2025, supported by rising public awareness and government programs.

North America
North America holds about 23% of the typhoid vaccine market, reflecting robust healthcare infrastructure and consistent demand for preventive travel vaccination.
For oral typhoid vaccines specifically, North America is the second-largest region with an estimated 27.4% market share in 2025.

Europe
Europe accounts for approximately 18% of the typhoid fever vaccine market (2023), with demand driven largely by travel medicine and vaccine adoption in developed countries.
The European market for oral typhoid vaccines is forecasted at around 19.8% share by 2025, tied to increasing awareness and regulatory support.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/typhoid-fever-market?prtk

Typhoid Fever segmentation :
By Drug Class:
Antibiotics: Primary treatment for typhoid fever; includes drugs like azithromycin and ciprofloxacin.
NSAIDs: Used to manage fever and inflammation in patients.
Others: Supportive treatments, including fluids and vitamins.

By Route of Administration:
Intravenous (IV): For severe cases requiring hospital care.
Others: Oral medications and other non-IV routes for outpatient treatment.

By End User:
Hospital Pharmacies: Supply drugs for inpatient care and severe cases.
Retail Pharmacies: Serve patients for outpatient prescriptions.
Online Pharmacies: Growing channel offering convenience and wider accessibility.

FAQ'S

1. What factors are driving the growth of the Typhoid Fever market?
The market growth is driven by increasing prevalence of typhoid in developing regions, rising demand for vaccines, improved diagnostic technologies, and heightened government initiatives for disease prevention.

2. Which regions dominate the Typhoid Fever market?
Asia-Pacific, particularly India and Southeast Asia, holds a significant market share due to high infection rates, while North America and Europe focus on vaccine development and advanced diagnostics.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
An Typhoid Fever is a technology-driven solution that optimizes traffic flow, reduces congestion, enhances road safety, and monitors real-time transportation data using AI, IoT, and smart sensors.

This release was published on openPR.